INTRODUCTION
============

Chronic wounds are a major issue in modern medicine, with more than 4 million affected patients in the United States alone. Around \$50 billion USD is spent annually on their treatment \[[@b1-aps-2019-01571]\]. The complications of chronic wounds, which include infection, sepsis, and cancerization, sometimes lead to amputation. The patient's quality of life is reduced by pain and the need for frequent medication, as well as by functional and social limitations. Surgical reconstruction is often challenging, especially in patients with severe comorbidities, local infection, and a lack of local viable tissues. As a consequence, conservative treatment with surgical debridement followed by advanced medications is still a mainstay. However, in some patients, the re-epithelization process is extremely slow or absent due to comorbidities. In such cases, as well as in patients unwilling to undergo surgical intervention, regenerative medicine may be a viable option to speed up re-epithelization, possibly alleviating their symptoms.

Over the last decades, several indications for fat grafting have been described, including volume loss, breast augmentation, and reconstruction. More recently, a worldwide effort was undertaken to investigate the regenerative potential of adipose tissue \[[@b2-aps-2019-01571]\], which extended its use to wound healing, the treatment of radiation damage, and the treatment of peri-anal fistulas, with promising results \[[@b3-aps-2019-01571]\]. Nanofat grafting was originally described in 2013 for the purpose of skin rejuvenation \[[@b4-aps-2019-01571]\]. In the original technique, the fat was mechanically emulsified, leading to fragmentation of mature adipocytes, while retaining some adiposederived stem cells (ADSCs) \[[@b4-aps-2019-01571]\]. Nanofat grafting was subsequently used as an adjuvant therapy for complex wounds \[[@b5-aps-2019-01571]\]. Although the concentration of ADSCs in a nanofat graft is lower than in non-fragmented fat, the nanofat may be injected with thinner needles, improving infiltration in fibro-sclerotic tissues. Moreover, a larger number of tunnels may be established, thus improving the contact surface with the vascularized tissue and promoting ADSC survival and proliferation. The cell fragments resulting from the emulsification process act as pro-inflammatory signals that trigger a regeneration cascade \[[@b4-aps-2019-01571],[@b6-aps-2019-01571]\]. However, there is still some reluctance to perform fat grafting of any kind in infected or infection-prone tissues.

Platelet-rich plasma (PRP) has been demonstrated to improve the proliferation and motility of ADSCs \[[@b7-aps-2019-01571],[@b8-aps-2019-01571]\], and several types of platelet derivatives, as well as multiple commercial kits, are currently available \[[@b9-aps-2019-01571]\]. However, conflicting evidence exists in the literature regarding the best PRP product and/or concentration to use to promote ADSC proliferation.

The aims of the present study were to develop a technique to maximize the regenerative and antimicrobial potential of a combination of ADSCs and PRP and to assess the efficacy of this combination in the treatment of nonhealing infected wounds. The authors' clinical experience is described.

METHODS
=======

Patients
--------

This prospective open-label study was approved by the local institutional review board. Fourteen patients were prospectively enrolled between March 2013 and July 2015 according to the following criteria. The inclusion criteria were a surgical or medical contraindication for major surgery, lack of response to one surgical debridement and advanced medications (polyurethane foam and/or alginate) for at least 3 months, and local infection that failed to respond to systemic antibiotic therapy. The exclusion criterion was life-threatening operatory risk. All patients provided informed consent. Pain reduction was assessed using a visual analog scale (VAS). Patients' demographic characteristics are summarized in [Table 1](#t1-aps-2019-01571){ref-type="table"}. The mean age of the patients ( ± standard deviation) was 73.86 ± 9 years. The mean initial wound size was 64.9 ± 111 cm^2^, while the mean initial wound depth was 8.93 ± 9.25 mm. The mean initial VAS score was 4.17 ± 0.75. Patients were followed up for 12 months ([Table 1](#t1-aps-2019-01571){ref-type="table"}).

Technique
---------

First, we reviewed the literature for information regarding each step of fat processing (e.g., infiltration) and PRP preparation with the goal of increasing ADSC number, viability, and proliferation. Then, we developed the following technique according to findings from the literature. First, the lower abdomen was infiltrated with a tumescent solution containing 1,000 mL of NaCl solution, 225 mg of ropivacaine (AstraZeneca, Basiglio, Italy), and 1 mg of epinephrine (Salf, Cenate Sotto, Italy). A 3-mm-wide multiperforated cannula with 1-mm lateral holes was used for fat harvesting. The fat was then decanted for 10 minutes and mechanically emulsified by shifting 30 times between two syringes connected by a 90° Luer-lock connector. No filtration was performed. A 27-gauge needle was chosen for re-injection. Blood was taken before starting the surgical procedure. Non-activated leukocyte-rich PRP (naLR-PRP) was extracted as previously described \[[@b10-aps-2019-01571]\] and was then added to the modified nanofat graft at a 20% concentration. The modifications to the conventional nanofat technique \[[@b4-aps-2019-01571]\] are summarized in [Table 2](#t2-aps-2019-01571){ref-type="table"}.

The treatment protocol was as follows: first, the wound was surgically debrided, and a solution of 80% nanofat and 20% naLR-PRP was injected in the wound bed and margins, both intradermally and subcutaneously. Injection was stopped when slight blanching of the tissue was noticed, and a paraffin-embedded gauze was then applied. Two weeks postoperatively, the patients underwent three sessions of 8-mL naLR-PRP injection performed at 2-week intervals. The co-primary endpoints were wound area reduction and wound depth reduction 3 months after surgery.

RESULTS
=======

Thirteen of the 14 patients completed the follow-up. One patient died from causes unrelated to the surgical procedure. Complete healing was achieved in seven patients (53.8%) with a mean time to re-epithelization of 9.1 ± 0.6 weeks. Four patients (30.8%) showed improvement, with a mean ulcer width reduction of 57.5% ± 13.8%. Two cases (15.4%) exhibited no change in ulcer width. A clinical improvement in perilesional skin quality was reported in all patients, with reduced erythema, increased thickness, and increased pliability.

An overall wound depth reduction of 76.6% ± 40.8% was found ([Fig. 1](#f1-aps-2019-01571){ref-type="fig"}).

Pain was fully alleviated in all patients who underwent re-epithelization. A mean pain reduction (as indicated by VAS score) of 42% ± 33.3% was observed in non-re-epithelized patients at 3 months postoperatively ([Figs. 2](#f2-aps-2019-01571){ref-type="fig"}, [3](#f3-aps-2019-01571){ref-type="fig"}).

DISCUSSION
==========

Chronic wounds are both common and challenging. In patients with such wounds, it is paramount to speed up healing, which may alleviate symptoms. Although both nanofat grafting and PRP have been reported to promote wound healing individually, to date a limited body of evidence exists regarding their use in combination. Combining nanofat and PRP into a single, injectable product adds more technical variables, such as ideal proportions, ideal concentrations, the optimal form of PRP to use, and so on. The technique described herein addresses these variables and describe the outcomes of the combination therapy. In our cohort of nonhealing patients, this technique allowed us to achieve both re-epithelization and pain reduction. Our approach exhibits several advantages over other techniques. Macro-fat grafting has regenerative potential \[[@b2-aps-2019-01571]\] but also has several drawbacks. The cell take in the recipient site is limited by local perfusion and tissue compliance, according to the principle of the graft-to-capacity ratio \[[@b11-aps-2019-01571]\]. Mature adipocytes are less prone to inducing regeneration than the stromal vascular fraction \[[@b3-aps-2019-01571]\]. Moreover, they comprise a large portion of the fat graft and can theoretically "steal" metabolites from the ADSCs to facilitate their own take. As a consequence, reducing the content of mature adipocytes in the injected material may theoretically allow for better survival and differentiation of ADSCs. The nanofat grafting technique \[[@b4-aps-2019-01571]\] allows mature adipocytes to be discarded, preserving the ADSCs. Nevertheless, the ADSC content is lower than in macro-fat grafting. In our approach, harvesting and processing were optimized according to the available literature to overcome such limitations and to improve cell content, viability, and take ([Table 2](#t2-aps-2019-01571){ref-type="table"}). The fat was harvested from the lower abdomen, as this has been reported to be the region with the highest ADSC concentration \[[@b12-aps-2019-01571],[@b13-aps-2019-01571]\], although no statistically significant difference in viability has been found compared to other donor sites \[[@b14-aps-2019-01571]\]. Lidocaine has previously been demonstrated to reduce ADSC proliferation and viability, while ropivacaine has been shown to have a negligible effect \[[@b15-aps-2019-01571]-[@b18-aps-2019-01571]\]. Epinephrine has not been shown to exhibit any cytotoxic effect \[[@b19-aps-2019-01571]\] and was used in the infiltration solution.

Aspiration was performed according to the micro-fat technique by means of a 3-mm cannula with 1-mm lateral holes. Such an approach has been shown to yield a higher ADSC concentration than a macro-fat approach \[[@b20-aps-2019-01571]\]. Rather than being centrifuged, the harvested micro-fat was decanted for 10 minutes to avoid any possible loss or viability impairment of the ADSCs \[[@b21-aps-2019-01571]\]. The lipoaspirate was then mechanically emulsified by shifting the fat 30 times between two syringes connected by a 90° Luer-lock connector. No filtration was performed to avoid any loss of ADSCs and to retain the cell fragments resulting from the emulsification process, which may act as pro-inflammatory signals that trigger a regeneration cascade \[[@b4-aps-2019-01571],[@b6-aps-2019-01571]\]. The resulting product was injectable with a 27-gauge needle, allowing for easy tunneling in cases of advanced fibrosis. To accelerate the regenerative process, we combined the fat derivative with PRP \[[@b7-aps-2019-01571],[@b22-aps-2019-01571],[@b23-aps-2019-01571]\]. PRP promotes ADSC survival and proliferation both indirectly through neoangiogenesis and directly through the release of factors such as platelet-derived growth factors and transforming growth factor beta \[[@b8-aps-2019-01571]\]. Atashi et al. \[[@b23-aps-2019-01571]\] demonstrated that 20% non-activated PRP (naPRP) was the most effective concentration in promoting ADSC proliferation, while activated PRP showed inconsistent results. We therefore chose naPRP in our clinical protocol. The naPRP was extracted before starting the surgical procedure to avoid any platelet reduction or activation following the surgical trauma. Specifically, leukocyte-rich PRP (LR-PRP) was chosen, with the expectation that its local antimicrobial activity would support the systemic antibiotic therapy. Such an antibiotic effect was previously demonstrated to be comparable to those of gentamicin and oxacillin against methicillin-sensitive *Staphylococcus aureus*. In the same study, LR-PRP was shown to inhibit the growth of methicillin-resistant *S. aureus* and *Escherichia coli* \[[@b22-aps-2019-01571]\]. The aforementioned modified nanofat graft also plays an antibiotic role. Adipocyte extracts were found to inhibit the growth of *S. aureus* and *Pseudomonas aeruginosa* by means of the antimicrobial peptide cathelicidin \[[@b24-aps-2019-01571],[@b25-aps-2019-01571]\]. Interestingly, in those findings, cathelicidin production initially increased in response to infection, then declined as the adipocytes matured, leading to the deduction that ADSCs or pre-adipocytes were responsible for its production. ADSC-derived cathelicidin and LR-PRP (20% naLR-PRP) may thus have a synergic antimicrobial effect. Altogether, the reported refinements were made to facilitate improved regenerative and antimicrobial potentials. The technique proved to be effective, as it promoted the healing of infected, surgically-untreatable chronic wounds unresponsive to conventional therapies. In an era of increasing healthcare costs, our approach may reduce the healing time and consequently the patient's distress, the risk of complications, and overall medical expenses. The main weaknesses of this study are the lack of a control group (e.g., PRP alone, nanofat graft alone, negative-pressure wound therapy, etc.) and the small sample size, which hampered subgroup analysis regarding the type of infection and the ulcer etiology. Moreover, different treatments or methods of dressing for 3 months in actual clinical trials may yield similar or better results. Comparison with other therapies was not among the aims of the present study, but it may be an interesting topic for future analyses. In our cohort of patients, we demonstrated that modified nanofat grafting with 20% naLR-PRP facilitated healing in patients previously unresponsive to antibiotic therapy, surgical debridement, and advanced medications.
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###### 

Patients' demographic characteristics

  Patient No.   Age (yr)   Sex   Ulcer site                Ulcer etiology   Preoperative wound size (cm)   Preoperative wound depth (mm)   Wound depth 3 months postoperatively (mm)   Area of re- epithelization 3 months postoperatively (%)   Pathogen
  ------------- ---------- ----- ------------------------- ---------------- ------------------------------ ------------------------------- ------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------
  1             76         F     Inferior limb             Vasculitis       30 × 15                        7                               2                                           65                                                        *Staphylococcus simulans, Pseudomonas aeruginosa*
  2             86         M     Inferior limb             Vascular         7 × 6                          4                               0                                           100                                                       *Proteus mirabilis*
  3             79         M     Inferior limb             Vascular         7 × 4                          6                               0                                           100                                                       *P. mirabilis*
  4             81         F     Lateral-cervical region   Cobaltotherapy   5 × 5                          7                               7                                           0                                                         *P. aeruginosa, Alcaligenes faecalis, Corynebacterium striatum*
  5             78         M     Sacral region             Pressure sore    9 × 7                          25                              10                                          48                                                        *Enterococcus faecium, P. mirabilis, P. aeruginosa*
  6             79         M     Inferior limb             Post-traumatic   8 × 4                          5                               0                                           100                                                       *P. mirabilis*
  7             71         F     Inferior limb             Post-traumatic   6 × 4                          5                               0                                           100                                                       *P. aeruginosa*
  8             68         F     Sacral region             Pressure sore    7 × 4                          35                              33                                          0                                                         *P. mirabilis, Enterococcus faecalis, Enterococcus avium*
  9             75         F     Inferior limb             Post-traumatic   5 × 3                          3                               0                                           100                                                       *Staphylococcus aureus* (MRSA)
  10            59         F     Inferior limb             Post-traumatic   7 × 6                          5                               0                                           100                                                       *S. aureus* (MRSA)
  11            60         M     Sacral region             Pressure sore    8 × 5                          4                               Deceased                                    Deceased                                                  *Staphylococcus epidermis*
  12            78         F     Inferior limb             Vascular         9 × 7                          8                               1                                           73                                                        *P. aeruginosa, S. aureus* (MRSA), *Morganella morganii, Streptococcus agalactiae*
  13            60         F     Inferior limb             Vascular         6 × 4                          4                               0                                           100                                                       *S. epidermis*
  14            84         M     Inferior limb             Vascular         8 × 4                          7                               2                                           44                                                        *P. aeruginosa, S. simulans*

M, male; F, female; MRSA, methicillin-resistant *S. aureus*.

###### 

Modified nanofat grafting technique

  Step           Technique
  -------------- -----------------------------------------------------------------------
  Infiltration   1,000 mL of NaCl solution, 225 mg of ropivacaine, 1 mg of epinephrine
  Donor site     Lower abdomen
  Aspiration     3-mm cannula with 1-mm holes connected to a Luer-lock syringe
  Processing     Decantation and mechanical emulsification, then addition of naLR- PRP
  Injection      27-Gauge syringe

naLR-PRP, non-activated leukocyte-rich platelet-rich plasma.
